US Markets
AZN

Venezuela will not authorise AstraZeneca COVID-19 vaccine due to 'effects on patients', VP says

Venezuela will not authorise AstraZeneca's COVID-19 vaccine, Vice President Delcy Rodriguez said on Monday, citing unspecified "effects on patients."

Adds details, context

CARACAS, March 15 (Reuters) - Venezuela will not authorise AstraZeneca's AZN.L COVID-19 vaccine, Vice President Delcy Rodriguez said on Monday, citing unspecified "effects on patients."

Rodriguez' comments came after several European countries paused inoculations using the vaccine following reports of blood coagulation in recipients. Other countries, including Canada and Australia, have continued to recommend its use.

Venezuela has so far used Russia's Sputnik V and China's Sinopharm in its vaccination programme.

The government had been in talks with political opposition - recognised as the South American nation's legitimate interlocutors by many Western countries - over a possible deal to participate in the World Health Organization's (WHO) Covax initiative, which provides vaccines to poor countries.

While no deal has been reached so far, AstraZeneca supplies one of the main vaccines used in the Covax initiative.

Rodriguez also said she had met with a representative of the Pan-American Health Organization to reiterate the government's demand that Britain release gold frozen in Venezuela's accounts in the country to facilitate payments for Covax vaccines.

(Reporting by Vivian Sequera in Caracas; Writing by Luc Cohen; Editing by Kim Coghill and Kenneth Maxwell)

((luc.cohen@thomsonreuters.com; +58 424 133 7696; Reuters Messaging: Twitter: @cohenluc))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Latest US Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More